Articles

CD19-Targeted 19-28z CAR-Modified T-Cells in Adult Patients with Relapsed/Refractory B-Cell ALL: Impact of MRD-Negative CR and Allogeneic Stem-Cell Transplant on Outcomes

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Frontline Inotuzumab Ozogamicin plus Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with ALL

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Dose-Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated ALL: A DFCI ALL Consortium Phase 2 Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Total Therapy GIMEMA LAL 1509 Protocol for De Novo Adult Ph+ ALL Patients: Updated Results and Genetic-Based Prognostic Stratification

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Frontline Hyper-CVAD plus Ofatumumab for Adult Patients with CD-20–Positive ALL

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Final Results of the OPTIM Imatinib Study in Patients with CML: Personalized Daily Doses of Imatinib by Therapeutic Drug Monitoring

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory ALL Treated with Blinatumomab

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Single-Agent Clofarabine versus Standard Daunorubicin/Cytarabine Regimen As Induction and Consolidation Therapy in Older Adults with Newly Diagnosed AML: Results of the Phase 3 E2906 Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Clofarabine-Based Consolidation in Younger Adults with AML in First Remission: Results of the Randomized ALFA-0702/CLARA Study

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Intermediate-Dose Cytarabine/Mitoxantrone versus Standard-Dose Cytarabine/Daunorubicin Induction Therapy in AML Patients >60 Years: Results from the SAL 60+ Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Page 176 of 329